Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
18
08
2019
accepted:
16
12
2019
revised:
07
11
2019
pubmed:
15
1
2020
medline:
5
1
2021
entrez:
15
1
2020
Statut:
ppublish
Résumé
The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes in tumour immunity post anti-VEGF therapy. The frequencies of immune cell populations and hypoxic conditions in the resistant murine tumours and clinical samples were examined. The expression profiles of both the proteins and genes in the resistant tumours were analysed. The impact of granulocyte-monocyte colony-stimulating factor (GM-CSF) expression on myeloid-derived suppressor cell (MDSC) function in the resistant tumours was evaluated. We found a marked increase and reduction in the number of Gr-1 + MDSCs and CD8 + lymphocytes in the resistant tumour, and the MDSCs preferentially infiltrated the hypoxic region. Protein array analysis showed upregulation of GM-CSF post anti-VEGF therapy. GM-CSF promoted migration and differentiation of MDSCs, which inhibited the CD8 + lymphocyte proliferation. Anti-GM-CSF therapy improved the anti-VEGF therapy efficacy, which reduced the infiltrating MDSCs and increased CD8 + lymphocytes. In immunohistochemical analysis of clinical samples, GM-CSF expression and MDSC infiltration was enhanced in the bevacizumab-resistant case. The anti-VEGF therapy induces tumour hypoxia and GM-CSF expression, which recruits MDSCs and inhibits tumour immunity. Targeting the GM-CSF could help overcome the anti-VEGF therapy resistance in ovarian cancers.
Sections du résumé
BACKGROUND
The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes in tumour immunity post anti-VEGF therapy.
METHODS
The frequencies of immune cell populations and hypoxic conditions in the resistant murine tumours and clinical samples were examined. The expression profiles of both the proteins and genes in the resistant tumours were analysed. The impact of granulocyte-monocyte colony-stimulating factor (GM-CSF) expression on myeloid-derived suppressor cell (MDSC) function in the resistant tumours was evaluated.
RESULTS
We found a marked increase and reduction in the number of Gr-1 + MDSCs and CD8 + lymphocytes in the resistant tumour, and the MDSCs preferentially infiltrated the hypoxic region. Protein array analysis showed upregulation of GM-CSF post anti-VEGF therapy. GM-CSF promoted migration and differentiation of MDSCs, which inhibited the CD8 + lymphocyte proliferation. Anti-GM-CSF therapy improved the anti-VEGF therapy efficacy, which reduced the infiltrating MDSCs and increased CD8 + lymphocytes. In immunohistochemical analysis of clinical samples, GM-CSF expression and MDSC infiltration was enhanced in the bevacizumab-resistant case.
CONCLUSIONS
The anti-VEGF therapy induces tumour hypoxia and GM-CSF expression, which recruits MDSCs and inhibits tumour immunity. Targeting the GM-CSF could help overcome the anti-VEGF therapy resistance in ovarian cancers.
Identifiants
pubmed: 31932754
doi: 10.1038/s41416-019-0725-x
pii: 10.1038/s41416-019-0725-x
pmc: PMC7078258
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
778-788Références
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81
pubmed: 27044098
Anticancer Res. 2006 Jul-Aug;26(4B):2785-9
pubmed: 16886597
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Blood. 2008 Apr 15;111(8):4233-44
pubmed: 18272812
J Biol Chem. 2006 Jan 13;281(2):951-61
pubmed: 16278208
Nat Immunol. 2013 Mar;14(3):211-20
pubmed: 23354483
Am J Prev Med. 2016 Mar;50(3):384-394
pubmed: 26541098
Blood. 1998 Dec 1;92(11):4150-66
pubmed: 9834220
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
pubmed: 11309499
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Mol Cancer Res. 2009 Feb;7(2):210-20
pubmed: 19208743
Int J Immunopathol Pharmacol. 2017 Jun;30(2):152-162
pubmed: 28534709
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Exp Mol Med. 2016 Jul 01;48(7):e242
pubmed: 27364892
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nat Biotechnol. 2007 Aug;25(8):911-20
pubmed: 17664940
Cancer Res. 2013 Nov 1;73(21):6413-23
pubmed: 24030977
Breast Cancer Res Treat. 2010 Aug;123(1):39-49
pubmed: 19898981
Clin Cancer Res. 2017 Jan 15;23(2):587-599
pubmed: 27401249
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Pharmacol Rev. 2015;67(2):441-61
pubmed: 25769965
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Int J Mol Sci. 2017 Dec 07;18(12):
pubmed: 29215599
Nat Commun. 2018 Apr 27;9(1):1685
pubmed: 29703902
Stem Cells. 2010 Jan;28(1):164-73
pubmed: 19911426
Cancer Discov. 2016 Aug;6(8):886-99
pubmed: 27184426
Immunity. 2016 Nov 15;45(5):963-973
pubmed: 27851925
Acta Oncol. 1991;30(8):889-902
pubmed: 1777242
Clin Cancer Res. 2013 Mar 15;19(6):1363-74
pubmed: 23340297
Cancer Res. 2017 Apr 1;77(7):1599-1610
pubmed: 28202513
Oncologist. 2007;12 Suppl 2:22-6
pubmed: 18039636
Cancer Cell. 2013 Aug 12;24(2):229-41
pubmed: 23871637
Eur J Immunol. 2010 Nov;40(11):2969-75
pubmed: 21061430
Cancer Gene Ther. 2016 Jun;23(6):188-98
pubmed: 27199222
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
Cancer Res. 2012 May 1;72(9):2239-50
pubmed: 22406619
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Clin Cancer Res. 2017 Jul 15;23(14):3794-3801
pubmed: 28159814
Mol Cell Biol. 1990 Mar;10(3):1281-6
pubmed: 2406568
Gynecol Oncol. 2015 Oct;139(1):10-6
pubmed: 26271155
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038